Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POU2F2 | P09086 | 5/20 | 0.53 |
| ▸ | SLC22A2 | O15244 | 13/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.43 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22469132 | 1.00 | POU2F2 (0.53) | POU2F2SLC22A2CYP3A4TMEM97ABCG2 | |
| SCHEMBL22469103 | 0.94 | POU2F2 (0.60) | POU2F2SLC22A2CYP3A4TMEM97ABCG2 | |
| SCHEMBL22469580 | 0.94 | POU2F2 (0.60) | POU2F2SLC22A2CYP3A4TMEM97ABCG2 | |
| SCHEMBL22482667 | 0.94 | POU2F2 (0.60) | POU2F2SLC22A2CYP3A4TMEM97ABCG2 | |
| SCHEMBL25674224 | 0.93 | POU2F2 (0.51) | POU2F2SLC22A2CYP3A4TMEM97ABCG2 | |
| SCHEMBL25673951 | 0.93 | POU2F2 (0.51) | POU2F2SLC22A2CYP3A4TMEM97ABCG2 | |
| SCHEMBL24521788 | 0.91 | POU2F2 (0.60) | POU2F2SLC22A2CYP3A4TMEM97ABCG2 | |
| SCHEMBL22527343 | 0.90 | POU2F2 (0.50) | POU2F2SLC22A2CYP3A4TMEM97ABCG2 | |
| SCHEMBL22469904 | 0.90 | POU2F2 (0.50) | POU2F2SLC22A2CYP3A4TMEM97ABCG2 | |
| SCHEMBL25673935 | 0.87 | POU2F2 (0.52) | POU2F2SLC22A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230027019-A1 | BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE | GILEAD SCIENCES INC (US) | 2023-01-26 | — | — | US | disclosed |
| EP-4122537-A1 | BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE | Gilead Sciences, Inc. (US) | 2023-01-25 | — | — | EP | disclosed |
| US-11084832-B2 | Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use | GILEAD SCIENCES, INC. (US) | 2021-08-10 | — | — | US | disclosed |
| US-20200317689-A1 | BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE | GILEAD SCIENCES, INC. | 2020-10-08 | — | — | US | disclosed |
| WO-2020197991-A1 | BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE | GILEAD SCIENCES, INC. (US) | 2020-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230027019-A1 | BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE | ZYX, CCNY, XDH | POU2F2 4781/4885SLC22A2 2554/4885CYP3A4 52/4885 |
| US-20200317689-A1 | BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE | ZYX, CCNY, XDH | POU2F2 4781/4885SLC22A2 2554/4885CYP3A4 52/4885 |
| US-11084832-B2 | Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use | ZYX, CCNY, XDH | POU2F2 4781/4885SLC22A2 2554/4885CYP3A4 52/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.